BNP Paribas Financial Markets’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-9,011
| Closed | -$215K | – | 4156 |
|
|
2021
Q1 | $215K | Sell |
9,011
-4,203
| -32% | -$78.1K | ﹤0.01% | 3008 |
|
|
2020
Q4 | $193K | Sell |
13,214
-2,893
| -18% | -$38.3K | ﹤0.01% | 2900 |
|
|
2020
Q3 | $229K | Sell |
16,107
-72,443
| -82% | -$1.11M | ﹤0.01% | 2699 |
|
|
2020
Q2 | $1.3M | Buy |
88,550
+71,495
| +419% | +$726K | ﹤0.01% | 1679 |
|
|
2020
Q1 | $70.3K | Buy |
17,055
+9,150
| +116% | +$42.9K | ﹤0.01% | 3385 |
|
|
2019
Q4 | $38K | Sell |
7,905
-503
| -6% | -$2.77K | ﹤0.01% | 3794 |
|
|
2019
Q3 | $51K | Buy |
8,408
+2,274
| +37% | +$14.2K | ﹤0.01% | 3467 |
|
|
2019
Q2 | $39.8K | Sell |
6,134
-4,657
| -43% | -$32.8K | ﹤0.01% | 3565 |
|
|
2019
Q1 | $76.5K | Buy |
10,791
+10,772
| +56,695% | +$70.9K | ﹤0.01% | 3275 |
|
|
2018
Q4 | $92 | Sell |
19
-1,851
| -99% | -$9.64K | ﹤0.01% | 4192 |
|
|
2018
Q3 | $13.7K | Sell |
1,870
-182
| -9% | -$1.33K | ﹤0.01% | 3601 |
|
|
2018
Q2 | $13.1K | Sell |
2,052
-9,026
| -81% | -$59.7K | ﹤0.01% | 3670 |
|
|
2018
Q1 | $60.3K | Buy |
11,078
+293
| +3% | +$1.46K | ﹤0.01% | 3465 |
|
|
2017
Q4 | $45K | Buy |
10,785
+5,333
| +98% | +$32.1K | ﹤0.01% | 3720 |
|
|
2017
Q3 | $52.5K | Sell |
5,452
-331
| -6% | -$3.44K | ﹤0.01% | 3123 |
|
|
2017
Q2 | $68.4K | Buy |
5,783
+4,638
| +405% | +$59.3K | ﹤0.01% | 3020 |
|
|
2017
Q1 | $14.7K | Sell |
1,145
-433
| -27% | -$5.21K | ﹤0.01% | 3097 |
|
|
2016
Q4 | $19.3K | Sell |
1,578
-1,112
| -41% | -$13.2K | ﹤0.01% | 3195 |
|
|
2016
Q3 | $31.7K | Buy |
2,690
+1,142
| +74% | +$11K | ﹤0.01% | 2651 |
|
|
2016
Q2 | $13.5K | Buy |
+1,548
| New | +$10.6K | ﹤0.01% | 2760 |
|
|
2016
Q1 | – | Sell |
-7,994
| Closed | -$62K | – | 3258 |
|
|
2015
Q4 | $62K | Sell |
7,994
-861
| -10% | -$6.61K | ﹤0.01% | 2652 |
|
|
2015
Q3 | $69.7K | Buy |
8,855
+5,349
| +153% | +$49.5K | ﹤0.01% | 2634 |
|
|
2015
Q2 | $31.8K | Buy |
3,506
+2,521
| +256% | +$25.4K | ﹤0.01% | 2754 |
|
|
2015
Q1 | $12.8K | Buy |
+985
| New | +$12.9K | ﹤0.01% | 2612 |
|
|
2014
Q4 | – | Sell |
-2,738
| Closed | -$24.6K | – | 3506 |
|
|
2014
Q3 | $24.6K | Buy |
2,738
+2,544
| +1,311% | +$27.4K | ﹤0.01% | 3027 |
|
|
2014
Q2 | $2.63K | Buy |
+194
| New | +$2.02K | ﹤0.01% | 2945 |
|
|
2014
Q1 | – | Sell |
-464
| Closed | -$6.18K | – | 3942 |
|
|
2013
Q4 | $6.18K | Buy |
+464
| New | +$5.63K | ﹤0.01% | 2962 |
|
|
2013
Q3 | – | Sell |
-12,104
| Closed | -$125K | – | 2770 |
|
|
2013
Q2 | $125K | Buy |
+12,104
| New | +$167K | ﹤0.01% | 2488 |
|
BNP Paribas Financial Markets's GNMK Position: Q2 2021 in Review
BNP Paribas Financial Markets sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 9,011 shares — an estimated $215K sold.
BNP Paribas Financial Markets first reported a position in GNMK in Q2 2013 and held it in 28 quarters. The position peaked at $1.3M in Q2 2020. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- BNP Paribas Financial Markets reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- BNP Paribas Financial Markets sold 9,011 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $215K.
- BNP Paribas Financial Markets first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 28 quarters.
- BNP Paribas Financial Markets's GenMark Diagnostics, Inc position peaked at $1.3M in Q2 2020.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2021, filed 10 Aug 2021.